ALKi might enhance anti-CD47-mediated phagocytosis thanks to the induced immunogenic cell damage, potentially in the off-target resistant setting as well, thus providing a further approach to definitely eliminate TKIs-resistant and persistent cancer cells [17]. This evidence concerns the gene CD47 and cancer.